Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.70 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101396 | 0.89 | EGFR (0.78) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL4552551 | 0.89 | EGFR (0.77) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL6097895 | 0.87 | EGFR (0.71) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL6101815 | 0.87 | EGFR (0.71) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL6101019 | 0.85 | EGFR (0.68) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL6101040 | 0.83 | EGFR (0.75) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL4551995 | 0.82 | EGFR (0.94) | EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL4419839 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL4552362 | 0.81 | EGFR (0.69) | EGFRERBB2ERBB3ERBB4GAK | |
| SCHEMBL6099367 | 0.80 | EGFR (1.00) | EGFRERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699798-A4 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-1699798-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7064203-B2 | Di-substituted pyrrolotriazine compounds | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005065266-A2 | DI-SUBSTITUTED PYRROLOTRIAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197339-A1 | Di-substituted pyrrolotrizine compounds | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885ERBB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.